Trials / Completed
CompletedNCT05580042
Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
An Open-Label, Single Arm, Phase I Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- TWi Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study AC-1101-GA-001 is an early phase open-label study with a 4-week treatment and 2-week follow-up period (without treatment) to assess the safety, tolerability, and efficacy of AC-1101 gel in patients with Granuloma Annulare.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AC-1101 | For each patient, once daily (QD) |
Timeline
- Start date
- 2022-10-03
- Primary completion
- 2023-11-15
- Completion
- 2023-11-15
- First posted
- 2022-10-14
- Last updated
- 2024-10-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05580042. Inclusion in this directory is not an endorsement.